JP5752687B2 - Ｅｒｂｂ３の外部ドメインに対する抗体およびその使用 - Google Patents

Ｅｒｂｂ３の外部ドメインに対する抗体およびその使用 Download PDF

Info

Publication number
JP5752687B2
JP5752687B2 JP2012525756A JP2012525756A JP5752687B2 JP 5752687 B2 JP5752687 B2 JP 5752687B2 JP 2012525756 A JP2012525756 A JP 2012525756A JP 2012525756 A JP2012525756 A JP 2012525756A JP 5752687 B2 JP5752687 B2 JP 5752687B2
Authority
JP
Japan
Prior art keywords
antibody
erbb3
seq
antigen
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2012525756A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013506622A5 (https=
JP2013506622A (ja
Inventor
ビルギット ショーバール
ビルギット ショーバール
ウーリック ニールセン
ウーリック ニールセン
マイケル フェルトハウス
マイケル フェルトハウス
Original Assignee
メリマック ファーマシューティカルズ インコーポレーティッド
メリマック ファーマシューティカルズ インコーポレーティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43607614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5752687(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by メリマック ファーマシューティカルズ インコーポレーティッド, メリマック ファーマシューティカルズ インコーポレーティッド filed Critical メリマック ファーマシューティカルズ インコーポレーティッド
Publication of JP2013506622A publication Critical patent/JP2013506622A/ja
Publication of JP2013506622A5 publication Critical patent/JP2013506622A5/ja
Application granted granted Critical
Publication of JP5752687B2 publication Critical patent/JP5752687B2/ja
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2012525756A 2009-08-21 2010-08-23 Ｅｒｂｂ３の外部ドメインに対する抗体およびその使用 Ceased JP5752687B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23579909P 2009-08-21 2009-08-21
US61/235,799 2009-08-21
PCT/US2010/046364 WO2011022727A2 (en) 2009-08-21 2010-08-23 Antibodies against the ectodomain of erbb3 and uses thereof

Publications (3)

Publication Number Publication Date
JP2013506622A JP2013506622A (ja) 2013-02-28
JP2013506622A5 JP2013506622A5 (https=) 2013-10-10
JP5752687B2 true JP5752687B2 (ja) 2015-07-22

Family

ID=43607614

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012525756A Ceased JP5752687B2 (ja) 2009-08-21 2010-08-23 Ｅｒｂｂ３の外部ドメインに対する抗体およびその使用

Country Status (21)

Country Link
EP (1) EP2467164A2 (https=)
JP (1) JP5752687B2 (https=)
KR (1) KR20120059568A (https=)
CN (1) CN103002912A (https=)
AU (1) AU2010284018C1 (https=)
BR (1) BR112012003809A2 (https=)
CA (1) CA2771744A1 (https=)
CR (1) CR20120108A (https=)
DO (1) DOP2012000044A (https=)
EA (1) EA201200195A1 (https=)
EC (1) ECSP12011740A (https=)
IL (1) IL218097A0 (https=)
IN (1) IN2012DN01518A (https=)
MA (1) MA33582B1 (https=)
MX (1) MX336091B (https=)
NI (1) NI201200027A (https=)
PE (1) PE20121585A1 (https=)
SG (1) SG178509A1 (https=)
TN (1) TN2012000057A1 (https=)
WO (1) WO2011022727A2 (https=)
ZA (1) ZA201201195B (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101598229B1 (ko) 2007-02-16 2016-02-26 메리맥 파마슈티컬즈, 인크. Ｅｒｂｂ3에 대한 항체 및 이의 용도
EP2896632B1 (en) * 2009-11-13 2017-10-25 Daiichi Sankyo Europe GmbH Material and methods for treating or preventing HER-3 associated diseases
RS54795B1 (sr) 2009-12-22 2016-10-31 Roche Glycart Ag Anti-her3 antitela i njihova korišćenja
KR101798679B1 (ko) 2010-03-11 2017-11-16 메리맥 파마슈티컬즈, 인크. ３중 음성 및 기저형 유방암 치료 시의 ｅｒｂｂ３ 저해제의 용도
MX343227B (es) 2010-04-09 2016-10-28 Aveo Pharmaceuticals Inc Anticuerpos anti-erbb3.
AU2011290672B2 (en) 2010-08-20 2015-07-09 Novartis Ag Antibodies for epidermal growth factor receptor 3 (HER3)
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
IT1402149B1 (it) * 2010-10-04 2013-08-28 Ist Fisioterap Ospitalroma Uso di un fosfopeptide in grado di bloccare l interazione her3/p85 per il trattamento dei tumori iperesprimenti her2.
MX347981B (es) 2010-11-01 2017-05-22 Symphogen As Composicion de anticuerpos pan-her.
US8476409B2 (en) 2011-04-19 2013-07-02 Merrimack Pharmaceuticals, Inc. Bispecific anti-IGF-1R and anti-ErbB3 antibodies
JPWO2012176779A1 (ja) 2011-06-20 2015-02-23 協和発酵キリン株式会社 抗ｅｒｂＢ３抗体
PH12014500483A1 (en) 2011-09-30 2014-04-14 Regeneron Pharma Anti-erbb3 antibodies and uses thereof
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
JP6169085B2 (ja) 2011-10-06 2017-07-26 アベオ ファーマシューティカルズ， インコーポレイテッド 抗ｅｒｂｂ３抗体に対する腫瘍応答の推定
AU2012335543C1 (en) 2011-11-09 2017-12-14 Beijing Cotimes Biotech Co., Ltd., HER3 antibodies and uses thereof
EP3590538A1 (en) 2011-12-05 2020-01-08 Novartis AG Antibodies for epidermal growth factor receptor 3 (her3)
US20150037336A1 (en) * 2012-02-22 2015-02-05 U3 Pharma Gmbh Combination of hb-egf binding protein and egfr inhibitor
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
US20160232293A1 (en) * 2013-10-17 2016-08-11 Sanford-Burnham Medical Research Institute Drug sensitivity biomarkers and methods of identifying and using drug sensitivity biomarkers
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
JP6771385B2 (ja) 2014-02-28 2020-10-21 メルス ナムローゼ フェンノートシャップ 二重特異性抗体および医薬組成物
CN105367657B (zh) * 2014-08-14 2019-09-13 上海生物制品研究所有限责任公司 抗her3抗体、其制法及其应用
EP3191523B1 (en) 2014-09-08 2019-08-07 Yeda Research and Development Co., Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki)
WO2016038609A1 (en) * 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Anti-her3 antibodies and uses of same
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
SMT202100230T1 (it) 2015-10-23 2021-07-12 Fundacio Inst De Recerca Biomedica Irb Barcelona Molecole di legame che inibiscono la crescita tumorale
IL269656B2 (en) 2017-03-31 2024-06-01 Merus Nv Bispecific antibodies that bind ERBB-2 and ERBB3 for use in the treatment of cells with NRG1 fusion gene
JP7296891B2 (ja) 2017-05-17 2023-06-23 メルス ナムローゼ フェンノートシャップ 乳癌のためのＥｒｂＢ－２／ＥｒｂＢ－３二重特異性抗体と内分泌療法との組み合わせ
SG11202001050PA (en) 2017-08-09 2020-03-30 Merus Nv Antibodies that bind egfr and cmet
CA3072267A1 (en) 2017-08-09 2019-02-14 University Of Saskatchewan Her3 binding agents and uses thereof
GB201804094D0 (en) * 2018-03-14 2018-04-25 Ultrahuman Thirteen Ltd ERBB3 Binding agents
JP2021534811A (ja) * 2018-06-22 2021-12-16 シーアールディー ファーマシューティカルズ インコーポレイティド 抗ｈｅｒ３抗体およびその用途
JP7847132B2 (ja) * 2020-10-14 2026-04-16 江蘇恒瑞医薬股▲ふん▼有限公司 抗ｈｅｒ３抗体と抗ｈｅｒ３抗体薬物複合体及びその医薬用途
WO2022109404A1 (en) * 2020-11-20 2022-05-27 Actinium Pharmaceuticals, Inc. Her3 radioimmunotherapy for the treatment of solid cancers
AU2022293634A1 (en) * 2021-06-15 2024-01-18 Beijing Sinotau Bio-Pharmaceuticals Technology Co., Ltd. Anti-her3 antibody, antibody drug conjugate containing the same, and use thereof
WO2023198138A1 (zh) * 2022-04-13 2023-10-19 上海翰森生物医药科技有限公司 抗体或其抗原结合片段及其医药用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101598229B1 (ko) * 2007-02-16 2016-02-26 메리맥 파마슈티컬즈, 인크. Ｅｒｂｂ3에 대한 항체 및 이의 용도

Also Published As

Publication number Publication date
ECSP12011740A (es) 2013-02-28
PE20121585A1 (es) 2012-11-29
AU2010284018B2 (en) 2014-06-05
MX336091B (es) 2016-01-08
ZA201201195B (en) 2015-07-29
WO2011022727A3 (en) 2013-06-27
KR20120059568A (ko) 2012-06-08
MX2012002172A (es) 2012-05-29
TN2012000057A1 (en) 2013-09-19
JP2013506622A (ja) 2013-02-28
IN2012DN01518A (https=) 2015-06-05
EA201200195A1 (ru) 2012-12-28
BR112012003809A2 (pt) 2019-09-24
WO2011022727A2 (en) 2011-02-24
IL218097A0 (en) 2012-04-30
AU2010284018A1 (en) 2012-03-22
CA2771744A1 (en) 2011-02-24
NI201200027A (es) 2013-01-29
MA33582B1 (fr) 2012-09-01
CN103002912A (zh) 2013-03-27
SG178509A1 (en) 2012-04-27
AU2010284018C1 (en) 2015-10-15
DOP2012000044A (es) 2012-06-30
CR20120108A (es) 2012-06-05
EP2467164A2 (en) 2012-06-27

Similar Documents

Publication Publication Date Title
JP5752687B2 (ja) Ｅｒｂｂ３の外部ドメインに対する抗体およびその使用
US20240360243A1 (en) Antibodies against the ectodomain of erbb3 and uses thereof
JP2014522850A (ja) 上皮成長因子受容体（ｅｇｆｒ）に対する抗体及びその使用
HK1187283A (en) Antibodies against erbb3 and uses thereof
HK1138771B (en) Antibodies against erbb3 and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130821

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130821

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150204

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150410

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150427

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150520

R150 Certificate of patent or registration of utility model

Ref document number: 5752687

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

RVOP Cancellation by post-grant opposition